12 assets in Congenital Adrenal Hyperplasia

Therapeutic assets addressing Congenital Adrenal Hyperplasia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Hydrocortisone Congenital Adrenal Hyperplasia	University of Texas Southwestern Medical Center	P4	A (81)
Cortisone Congenital Adrenal Hyperplasia	Federico II University	P4	BBB (72)
Atumelnant Congenital Adrenal Hyperplasia	Crinetics Pharmaceuticals Inc.	P3	BB (70)
Fludrocortisone Congenital Adrenal Hyperplasia	University of Texas Southwestern Medical Center	P3	BB (69)
Dexasone Congenital Adrenal Hyperplasia	Shanghai Jiao Tong University School of Medicine	P4	BB (68)
Crinecerfont Congenital Adrenal Hyperplasia	Neurocrine Biosciences	P3	BB (66)
Prednisolone Congenital Adrenal Hyperplasia	Federico II University	P4	BB (65)
Prednisone Congenital Adrenal Hyperplasia	Shanghai Jiao Tong University School of Medicine	P4	BB (65)
Abiraterone Congenital Adrenal Hyperplasia	University of Texas Southwestern Medical Center	P2	B (60)
Aav Bbp-631 Congenital Adrenal Hyperplasia	Adrenas Therapeutics Inc	P1/2	CCC (48)
Lu Ag13909 Congenital Adrenal Hyperplasia	H. Lundbeck A/S	P1/2	CCC (48)
Tildacerfont Congenital Adrenal Hyperplasia	Spruce Biosciences	P2	CC (41)